9,000 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by JW Asset Management LLC

JW Asset Management LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,000 shares of the company’s stock, valued at approximately $707,000. Tarsus Pharmaceuticals makes up 0.3% of JW Asset Management LLC’s investment portfolio, making the stock its 20th biggest position.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $242,705,000. Jupiter Topco LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $176,834,000. Janus Henderson Group PLC lifted its position in shares of Tarsus Pharmaceuticals by 16.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock valued at $157,223,000 after buying an additional 310,638 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Tarsus Pharmaceuticals by 57.5% during the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after buying an additional 436,271 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at $23,249,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Tarsus Pharmaceuticals

In related news, Director William Link, PhD sold 12,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total value of $979,750.00. Following the completion of the sale, the director owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $87.50, for a total value of $278,250.00. Following the transaction, the insider owned 1,590 shares in the company, valued at approximately $139,125. The trade was a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 48,031 shares of company stock valued at $4,004,227. 9.64% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ TARS opened at $76.89 on Friday. The stock has a market cap of $3.79 billion, a PE ratio of -5.06 and a beta of 0.34. The company has a current ratio of 1.96, a quick ratio of 1.94 and a debt-to-equity ratio of 0.70. Tarsus Pharmaceuticals, Inc. has a 12-month low of $53.89 and a 12-month high of $91.53. The company has a 50-day moving average of $74.90 and a 200 day moving average of $67.92.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The business had revenue of $194.57 million during the quarter, compared to analysts’ expectations of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 24.51% and a negative net margin of 102.93%. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -15.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on TARS shares. The Goldman Sachs Group started coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price target for the company. Mizuho decreased their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Barclays started coverage on shares of Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They set an “overweight” rating and a $110.00 price objective on the stock. HC Wainwright lifted their target price on shares of Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Finally, Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $104.57.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company’s work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.